Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
Search
:::

藍耿欣 (Keng-Hsin Lan)

藍耿欣(Keng-Hsin Lan)圖 Return Appointment First Appointment

[Profile]

  • Education
    • M.D., National Yang-Ming University School of Medicine, Taipei, Taiwan,
  • Career and Experience
    Current Positions：
    • - Now, Attending Physician, Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • - Now, Associate Professor, National Yang-Ming Chiao-Tung University School of Medicine, Taipei, Taiwan,
    Experiences：
    • - , Chief Resident, Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • - , Resident, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
  • Medical Expertise
    1. 1. Chronic hepatitis B and C
    2. 2. Liver cirrhosis and its complications
    3. 3. Hepatocellular carcinoma – diagnosis & treatment
    4. 4. biliary tract disease
    5. 5. Abdominal ultrasound and GI tract endoscopy
  • License
    Board-certified Gastroenterologist and Instructor, Diploma of The Gastroenterological Society of Taiwan Board-certified Digestive Endoscopist and Instructor, Diploma of The Digestive Endoscopy Society of Taiwan

[Publications]

  1. Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH*. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. Am J Chin Med. 2018; 46:835-852. (*Corresponding author)
  2. Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH*. The Antiviral Effect of Saikosaponin B2 in combination with Daclatasvir on NS5A Resistance-associated Substitutions of Hepatitis C Virus. J Chin Med Assoc 2019; 82: 368-374. (*Corresponding author)
  3. Wang YK, Lee WP, Wang, YW, Huang YH, Hou MC, Chang YL, and Lan KH*. Precipitating factors causing hyperbilirubinemia in chronic hepatitis C treated with paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Chin Med Assoc 2020 Dec;83(12):1071-1078. (*Corresponding author)
  4. Wang YW, Lee WP, Huang, YH, Hou MC, Lan KH*. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis. 2021 Sep 21;21(1):984. (*Corresponding author)
  5. Wang, YK., Wang, YW., Lu, CL, Huang, YH., Hou, MC., Lee, WP*., Lan, KH*. Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. Sci Rep. 2022 Jun 15; 12(1):9942. (*Corresponding author).